Certain bottles and doses of duloxetine, a common antidepressant, have been recalled due to the presence of potentially cancer-causing chemicals. The recall was initiated on Nov. 19 by ...

For diabetic peripheral neuropathic pain, the recommended dosage is 60 mg per day, although dosages ... increase the risk of adverse effects. In duloxetine studies for any indication, there ...

Conclusion: In this open-label phase of a relapse prevention study, duloxetine (60 mg QD) was shown to be safe and effective in the treatment of MDD. This is an Open Access article distributed ...

Starting in October 2024, over 200,000 bottles of duloxetine delayed-release capsules were recalled over concerns about the presence of nitrosamines, which can increase the risk of cancer.